Research paper
Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.
Citations: 71
Influential: 1
Interventional (Human) Studies
82
Study answer
What this study found
EGCG produced sex-specific metabolic effects rather than a uniform benefit. Compared with placebo, resting postprandial fat oxidation was 40% higher in men and 21% lower in women, and during moderate exercise postprandial energy expenditure was lower after EGCG, indicating greater working efficiency. Muscle work efficiency increased from 21% with placebo to 27% with EGCG in men and from 20% to 25% in women; fasting adipose tissue lactate was lower with EGCG in men but not women, and triglycerides were significantly lower in men (P = 0.005). Overall, 12 weeks of EGCG modulated energy…
- Study & population
- Randomized, double-blind, placebo-controlled, crossover trial in adults with relapsing-remitting multiple sclerosis.
- Intervention
- Oral epigallocatechin-3-gallate (EGCG) 600 mg/day was given as 150 mg capsules twice daily, 1 hour before breakfast and dinner, for 12 weeks per treatment period in a randomized crossover comparison with placebo.
- Key limitation
- The study was very small and single-center, which limits precision and generalizability.
View source
Open PDFOriginal abstract
No abstract is available for this paper.